These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17139582

  • 21. [Differential therapy with oral antidiabetic drugs].
    Sachse G.
    Z Gesamte Inn Med; 1993 Mar; 48(3):127-9. PubMed ID: 8475635
    [Abstract] [Full Text] [Related]

  • 22. Insulin treatment and the problem of weight gain in type 2 diabetes.
    Carver C.
    Diabetes Educ; 2006 Mar; 32(6):910-7. PubMed ID: 17102158
    [Abstract] [Full Text] [Related]

  • 23. [Metformin role in the treatment of type 2 diabetes in 2008].
    Spada A, Philippe J.
    Rev Med Suisse; 2008 Jun 04; 4(160):1392-4, 1396-7. PubMed ID: 18630062
    [Abstract] [Full Text] [Related]

  • 24. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P.
    Diabetes Obes Metab; 2008 Dec 04; 10(12):1167-77. PubMed ID: 18494804
    [Abstract] [Full Text] [Related]

  • 25. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK, Holst JJ, Vilsbøll T.
    IDrugs; 2008 Jul 04; 11(7):497-501. PubMed ID: 18600596
    [Abstract] [Full Text] [Related]

  • 26. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S, COM06 Study Investigators.
    Nutr Metab Cardiovasc Dis; 2008 Jun 04; 18(5):373-9. PubMed ID: 17919894
    [Abstract] [Full Text] [Related]

  • 27. Is a failure to recognize an increase in food intake a key to understanding insulin-induced weight gain?
    Ryan M, Livingstone MB, Ducluzeau PH, Sallé A, Genaitay M, Ritz P.
    Diabetes Care; 2008 Mar 04; 31(3):448-50. PubMed ID: 18086874
    [Abstract] [Full Text] [Related]

  • 28. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct 04; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 29. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E, Schnell O.
    Diabetes Care; 2008 Feb 04; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract] [Full Text] [Related]

  • 30. Diabetes control without weight gain.
    Health News; 1999 Apr 15; 5(5):6. PubMed ID: 10214130
    [No Abstract] [Full Text] [Related]

  • 31. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb 15; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 32. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 15; 16(7):711-25. PubMed ID: 17551989
    [Abstract] [Full Text] [Related]

  • 33. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
    Bosi E.
    Diabetes Obes Metab; 2009 May 15; 11 Suppl 2():3-8. PubMed ID: 19385978
    [Abstract] [Full Text] [Related]

  • 34. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May 15; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 35. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug 15; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 36. Weight changes following the initiation of new anti-hyperglycaemic therapies.
    Nichols GA, Gomez-Caminero A.
    Diabetes Obes Metab; 2007 Jan 15; 9(1):96-102. PubMed ID: 17199724
    [Abstract] [Full Text] [Related]

  • 37. Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
    Russell-Jones D, Khan R.
    Diabetes Obes Metab; 2007 Nov 15; 9(6):799-812. PubMed ID: 17924864
    [Abstract] [Full Text] [Related]

  • 38. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
    Scheen AJ.
    Diabetes Metab; 2007 Feb 15; 33(1):3-12. PubMed ID: 17258489
    [Abstract] [Full Text] [Related]

  • 39. Metformin: old wine in new bottle--evolving technology and therapy in diabetes.
    Joshi SR.
    J Assoc Physicians India; 2005 Nov 15; 53():963-72. PubMed ID: 16515237
    [Abstract] [Full Text] [Related]

  • 40. The influence of antidiabetic medications on the development and progression of prostate cancer.
    Hitron A, Adams V, Talbert J, Steinke D.
    Cancer Epidemiol; 2012 Aug 15; 36(4):e243-50. PubMed ID: 22417708
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.